ABOS — Acumen Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1576885 ·
Last close
$2.42
Market Cap
$174.79M
52W High
$3.60
52W Low
$2.08
ADV30
324,125
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -21,149,000 | -20,737,000 | 133,629,000 | 51,796,000 | 46,153,000 |
| Dec 2025 | 0 | — | -25,199,000 | -25,138,000 | 122,833,000 | 53,989,000 | 52,403,000 |
| Sep 2025 | 0 | — | -26,513,000 | -26,451,000 | 142,221,000 | 46,832,000 | 49,048,000 |
| Jun 2025 | 0 | — | -41,750,000 | -40,950,000 | 171,897,000 | 36,810,000 | 54,820,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-115,538,000
Investing CF
$133,933,000
Financing CF
$-34,000
CapEx
$-88,000
Dividends Paid
—
Buybacks
$-73,000
EPS Diluted TTM
$-2.10
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-446,462,000
Inventory
—
Receivables
$625,000
ST Investments
$62,876,000
EBIT TTM
$-117,111,000
Pretax Income TTM
$-121,335,000
Interest Exp TTM
$4,224,000
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -123,832,000 | -121,335,000 | 122,833,000 | 52,403,000 | — | -115,538,000 |
| Dec 2024 | 0 | -114,017,000 | -102,329,000 | 238,992,000 | 57,176,000 | — | -86,215,000 |
| Dec 2023 | 0 | -61,138,000 | -52,371,000 | 310,125,000 | 43,152,000 | — | -43,064,000 |
| Dec 2022 | 0 | -45,237,000 | -42,856,000 | 196,587,000 | 7,812,000 | — | -35,153,000 |
TTM Snapshot
Revenues TTM
$6,628,000
NetIncome TTM
$-53,432,000
OpCashFlow TTM
$0
Assets (Latest)
$238,992,000
Forward EPS
$-1.52
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PLX | Protalix BioTherapeutics, Inc. | $172.42M | $2.14 | — |
| TNYA | Tenaya Therapeutics, Inc. | $169.69M | $0.78 | — |
| IPHA | Innate Pharma SA | $161.51M | $1.72 | — |
| DTIL | PRECISION BIOSCIENCES INC | $195.58M | $7.58 | — |
| VXRT | Vaxart, Inc. | $153.22M | $0.63 | — |
News headlines (Yahoo Finance, 1h cache)
Acumen Pharmaceuticals Inc (ABOS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
2026-05-12 19:01 · Yahoo
Acumen Pharmaceuticals Q1 Earnings Call Highlights
2026-05-12 13:07 · Yahoo
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-12 11:00 · Yahoo
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
2026-05-07 20:00 · Yahoo
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
2026-05-05 20:00 · Yahoo
Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-03-31 13:35 · Yahoo
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
2026-03-30 13:40 · Yahoo
Acumen Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
2026-03-27 12:30 · Yahoo
Acumen Pharmaceuticals Inc (ABOS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ...
2026-03-26 19:00 · Yahoo
Acumen Pharmaceuticals Q4 Earnings Call Highlights
2026-03-26 14:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.